Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
TB loaned the business money so that it didn't have to raise money and dilute holders. He needs to stay below the 30% level for legal reasons hence he sold to then convert and move back to the pre-conversion holding. Loaning the business money showed his confidence and he has not diluted shareholders. Nobody should be unhappy here, this will return to higher market cap in due coarse and then much higher over time as the significance of IQAIs products convert to sales, unless we get sold, I'm wondering if that's the reason behind the conversion...
Of course they’re ‘invested’, exactly how is anyone’s guess. Whilst we have no news it’s easy to play the no news, too late card, I’m not hearing anything other than that. When news comes they’ll need to re-adjust there positioning... wonder what that will be, I guess too late will work for a while until it’s clear we still need mass testing
also the standard of healthcare and access to vaccines is not the same. With flu you get vaccinated to last years flu, the flu vaccine has not eradicated the disease. COVID has a mortality rate 10x that of influenza, they are not the same type of virus. It's wrong to say that because Spanish flu went away and that we vaccinate against flu, that this current vaccination will be a short term solution. At best we have another 2-3 years of testing, but as I've said before, mutation means selective pressure on genotypes the vaccine doesn't stop... how do you follow those to map new outbreaks? testing. The world is in a pandemic. the world will need constant testing. this is here to stay.
"These findings suggest that the patient was infected by SARS-CoV-2 on two separate occasions by a genetically distinct virus. Thus, previous exposure to SARS-CoV-2 might not guarantee total immunity in all cases. All individuals, whether previously diagnosed with COVID-19 or not, should take identical precautions to avoid infection with SARS-CoV-2. The implications of reinfections could be relevant for vaccine development and application"
for example...
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30764-7/fulltext
Dream, we all hope the vaccines provide an escape for everyone and stops the deaths that are occurring. However, biology always wins out and as with other viruses I suspect this virus might outsmart us, it's only a matter of time. GDR has already seen a significant drop on 'your' sentiment. I suspect shortly we shall see that testing will outlive the first sets of vaccines.
I agree hulltiger, this is intriguing. There argument before the dividend announcement was that the cash was not reflected in the share price because since the RMS announcements, the share price had dropped from the 45-50p mark. We're now back up there. Why would this then drop 42.75p since as you say 42.75p was not added to the price in the first place.
I think a lot of spooked investors not knowing quite how to value this, time will tell! Roll on the 11th, if this does fall to 12p mark then that will be an oversell I think and I'll be reinvesting that dividend and tripling my holding for the next BRH investment to come good... I doubt that will happen but fingers crossed!
https://in.reuters.com/article/uk-factcheck-vaccine-idUSKBN27W2I7
A better source for you Furion, cell lines are as I suspected used for the production of the viral surrogate to deliver the mRNA into human cells for replication, but the cell lines referred to were not used for manufacture, MRC-5 was used to look at integration of the vector into cells, not the same thing.
There are enough unknowns about the use of these types of vaccines we need to get to the bottom of without additional nonsense, but sometimes you need to nonsense to investigate the depths, but let's filter them out quickly...
The issue is not LAMP as such, it's the fact that companies like OptiGene have never developed a clinical diagnostic before and had not appreciated some of the nuances around development, particularly with biological samples. Saliva has its particular aspects to take into account. Worse for LFDs because of the various proteins that clog the membranes they use. Genedrive will have encountered these issues before and know what OptiGene don't. Genedrive have years of development experience to bring to the table and will have methodically gone through the issues as part of their development program. Hoping they have their product out soon. The world needs it.
Interesting article with some good quotes from WHO, etc around the length of time the vaccine will need post introduction to work through the system and some of the what if's. Testing here for a longtime, the need for accurate diagnosis is essential and the LFT and OptiGene 'rush jobs' were are learning are not up to the mark. Genedrive has taken the time to make sure they have a gold standard performance. I hope time will show that DB has been ethical, responsible and has maintained integrity in making sure the product is fit for purpose. Genedrive's time to shine will come...
https://www.bbc.co.uk/news/resources/idt-b6360f40-84f9-469b-b6a3-a4568e161c4f